Literature DB >> 26224887

Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.

Jennie H M Yang1, Antony J Cutler2, Ricardo C Ferreira2, James L Reading3, Nicholas J Cooper2, Chris Wallace2, Pamela Clarke2, Deborah J Smyth2, Christopher S Boyce4, Guo-Jian Gao4, John A Todd2, Linda S Wicker2, Timothy I M Tree1.   

Abstract

Defective immune homeostasis in the balance between FOXP3+ regulatory T cells (Tregs) and effector T cells is a likely contributing factor in the loss of self-tolerance observed in type 1 diabetes (T1D). Given the importance of interleukin-2 (IL-2) signaling in the generation and function of Tregs, observations that polymorphisms in genes in the IL-2 pathway associate with T1D and that some individuals with T1D exhibit reduced IL-2 signaling indicate that impairment of this pathway may play a role in Treg dysfunction and the pathogenesis of T1D. Here, we have examined IL-2 sensitivity in CD4+ T-cell subsets in 70 individuals with long-standing T1D, allowing us to investigate the effect of low IL-2 sensitivity on Treg frequency and function. IL-2 responsiveness, measured by STAT5a phosphorylation, was a very stable phenotype within individuals but exhibited considerable interindividual variation and was influenced by T1D-associated PTPN2 gene polymorphisms. Tregs from individuals with lower IL-2 signaling were reduced in frequency, were less able to maintain expression of FOXP3 under limiting concentrations of IL-2, and displayed reduced suppressor function. These results suggest that reduced IL-2 signaling may be used to identify patients with the highest Treg dysfunction and who may benefit most from IL-2 immunotherapy.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26224887      PMCID: PMC4975524          DOI: 10.2337/db15-0516

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  46 in total

1.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Authors:  Michelle Rosenzwajg; Guillaume Churlaud; Roberto Mallone; Adrien Six; Nicolas Dérian; Wahiba Chaara; Roberta Lorenzon; S Alice Long; Jane H Buckner; Georgia Afonso; Hang-Phuong Pham; Agnès Hartemann; Aixin Yu; Alberto Pugliese; Thomas R Malek; David Klatzmann
Journal:  J Autoimmun       Date:  2015-01-26       Impact factor: 7.094

2.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

3.  Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource.

Authors:  Calliope A Dendrou; Vincent Plagnol; Erik Fung; Jennie H M Yang; Kate Downes; Jason D Cooper; Sarah Nutland; Gillian Coleman; Matthew Himsworth; Matthew Hardy; Oliver Burren; Barry Healy; Neil M Walker; Kerstin Koch; Willem H Ouwehand; John R Bradley; Nicholas J Wareham; John A Todd; Linda S Wicker
Journal:  Nat Genet       Date:  2009-08-23       Impact factor: 38.330

4.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Authors:  Agnès Hartemann; Gilbert Bensimon; Christine A Payan; Sophie Jacqueminet; Olivier Bourron; Nathalie Nicolas; Michèle Fonfrede; Michelle Rosenzwajg; Claude Bernard; David Klatzmann
Journal:  Lancet Diabetes Endocrinol       Date:  2013-10-08       Impact factor: 32.069

5.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.

Authors:  Yenkel Grinberg-Bleyer; Audrey Baeyens; Sylvaine You; Rima Elhage; Gwladys Fourcade; Sylvie Gregoire; Nicolas Cagnard; Wassila Carpentier; Qizhi Tang; Jeffrey Bluestone; Lucienne Chatenoud; David Klatzmann; Benoît L Salomon; Eliane Piaggio
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

6.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

7.  Follicular helper T cell signature in type 1 diabetes.

Authors:  Rupert Kenefeck; Chun Jing Wang; Tauseef Kapadi; Lukasz Wardzinski; Kesley Attridge; Louise E Clough; Frank Heuts; Alexandros Kogimtzis; Sapna Patel; Miranda Rosenthal; Masahiro Ono; David M Sansom; Parth Narendran; Lucy S K Walker
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

8.  Interaction between Treg apoptosis pathways, Treg function and HLA risk evolves during type 1 diabetes pathogenesis.

Authors:  Sanja Glisic; Parthav Jailwala
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

9.  Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes.

Authors:  Sefina Arif; Pia Leete; Vy Nguyen; Katherine Marks; Nurhanani Mohamed Nor; Megan Estorninho; Deborah Kronenberg-Versteeg; Polly J Bingley; John A Todd; Catherine Guy; David B Dunger; Jake Powrie; Abby Willcox; Alan K Foulis; Sarah J Richardson; Emanuele de Rinaldis; Noel G Morgan; Anna Lorenc; Mark Peakman
Journal:  Diabetes       Date:  2014-06-17       Impact factor: 9.461

10.  Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes.

Authors:  W S Thompson; M L Pekalski; H Z Simons; D J Smyth; X Castro-Dopico; H Guo; C Guy; D B Dunger; S Arif; M Peakman; C Wallace; L S Wicker; J A Todd; R C Ferreira
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more
  24 in total

1.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

2.  IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.

Authors:  Gavin Whitehouse; Elizabeth Gray; Sotiris Mastoridis; Elliot Merritt; Elisavet Kodela; Jennie H M Yang; Richard Danger; Marta Mairal; Sofia Christakoudi; Juan J Lozano; Iain C Macdougall; Timothy I M Tree; Alberto Sanchez-Fueyo; Marc Martinez-Llordella
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

3.  Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Authors:  Manuela Battaglia; Simi Ahmed; Mark S Anderson; Mark A Atkinson; Dorothy Becker; Polly J Bingley; Emanuele Bosi; Todd M Brusko; Linda A DiMeglio; Carmella Evans-Molina; Stephen E Gitelman; Carla J Greenbaum; Peter A Gottlieb; Kevan C Herold; Martin J Hessner; Mikael Knip; Laura Jacobsen; Jeffrey P Krischer; S Alice Long; Markus Lundgren; Eoin F McKinney; Noel G Morgan; Richard A Oram; Tomi Pastinen; Michael C Peters; Alessandra Petrelli; Xiaoning Qian; Maria J Redondo; Bart O Roep; Desmond Schatz; David Skibinski; Mark Peakman
Journal:  Diabetes Care       Date:  2019-11-21       Impact factor: 19.112

Review 4.  Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Authors:  Anabelle Visperas; Dario A A Vignali
Journal:  J Immunol       Date:  2016-11-15       Impact factor: 5.422

Review 5.  Genetics of type 1 diabetes.

Authors:  Maria J Redondo; Andrea K Steck; Alberto Pugliese
Journal:  Pediatr Diabetes       Date:  2017-11-02       Impact factor: 4.866

6.  Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.

Authors:  Katharine Schwedhelm; Jerill Thorpe; Sara A Murray; Marc Gavin; Cate Speake; Carla Greenbaum; Karen Cerosaletti; Jane Buckner; S Alice Long
Journal:  Clin Immunol       Date:  2017-06-20       Impact factor: 3.969

7.  Increased islet antigen-specific regulatory and effector CD4+ T cells in healthy individuals with the type 1 diabetes-protective haplotype.

Authors:  Xiaomin Wen; Junbao Yang; Eddie James; I-Ting Chow; Helena Reijonen; William W Kwok
Journal:  Sci Immunol       Date:  2020-02-14

8.  Peripherally induced regulatory T cells contribute to the control of autoimmune diabetes in the NOD mouse model.

Authors:  Cornelia Schuster; Franziska Jonas; Fangzhu Zhao; Stephan Kissler
Journal:  Eur J Immunol       Date:  2018-04-25       Impact factor: 5.532

Review 9.  Immunological biomarkers for the development and progression of type 1 diabetes.

Authors:  Chantal Mathieu; Riitta Lahesmaa; Ezio Bonifacio; Peter Achenbach; Timothy Tree
Journal:  Diabetologia       Date:  2018-09-12       Impact factor: 10.122

Review 10.  Function, Failure, and the Future Potential of Tregs in Type 1 Diabetes.

Authors:  Maria Bettini; Matthew L Bettini
Journal:  Diabetes       Date:  2021-05-20       Impact factor: 9.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.